{"id":44250,"date":"2022-05-24T07:04:07","date_gmt":"2022-05-24T05:04:07","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/data-at-the-2022-asco-annual-meeting-highlight-genentechs-continued-commitment-to-innovation-in-oncology-and-personalized-healthcare\/"},"modified":"2022-05-24T07:04:07","modified_gmt":"2022-05-24T05:04:07","slug":"data-at-the-2022-asco-annual-meeting-highlight-genentechs-continued-commitment-to-innovation-in-oncology-and-personalized-healthcare","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/data-at-the-2022-asco-annual-meeting-highlight-genentechs-continued-commitment-to-innovation-in-oncology-and-personalized-healthcare\/","title":{"rendered":"Data at the 2022 ASCO Annual Meeting Highlight Genentech\u2019s Continued Commitment to Innovation in Oncology and Personalized Healthcare"},"content":{"rendered":"
\n

\n\u2013 Pivotal data on glofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leading hematology portfolio \u2013<\/i>\n<\/p>\n

\n\u2013 Further studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presented \u2013<\/i>\n<\/p>\n

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 3-7, 2022. Genentech and its partners will present clinical studies across medicines, comprehensive genomic tests, and real-world data at this year\u2019s meeting.\n<\/p>\n

<\/a><\/p>\n

\n\u201cAt ASCO this year, progress from our portfolio, partnerships and collaborations showcase our commitment to advance innovation in cancer care,\u201d said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. \u201cWe\u2019re especially pleased to present data from our broad hematology portfolio, including pivotal data for glofitamab, a potential first-in-class bispecific antibody that may improve the lives of people with heavily pre-treated aggressive lymphoma.\u201d\n<\/p>\n

\nFocusing on improving outcomes in non-Hodgkin lymphoma<\/b>\n<\/p>\n

\nNew and updated data in non-Hodgkin lymphoma will be presented at ASCO. This includes pivotal data from the Phase II NP30179 study investigating glofitamab, an investigational CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with diffuse large B-cell lymphoma (DLBCL). DLBCL is an aggressive form of lymphoma, where as many as 40% of patients will relapse, at which point treatment options are limited and survival is shortened. Glofitamab is part of Genentech\u2019s broad bispecific antibody development program, which may offer a new immunotherapy-based approach to tackle a range of blood cancers. It is being investigated in several clinical trials including the STARGLO Phase III study, evaluating glofitamab in combination with gemcitabine and oxaliplatin (GemOx) versus MabThera\u00ae\/Rituxan\u00ae (rituximab) in combination with GemOx in autologous stem-cell transplant ineligible relapsed or refractory DLBCL. In addition, key findings from an analysis of the Asia subpopulation from the pivotal Phase III POLARIX study investigating Polivy\u00ae (polatuzumab vedotin) in combination with MabThera\/Rituxan plus cyclophosphamide, doxorubicin and prednisone (R-CHP) in people with newly diagnosed DLBCL will be featured. Polivy plus R-CHP is the first treatment regimen to significantly improve outcomes in previously untreated DLBCL in more than 20 years, potentially transforming treatment for people with this disease.\n<\/p>\n

\nDriving innovation in personalized cancer care<\/b>\n<\/p>\n

\nMore than 20 new pieces of research from partnerships with Foundation Medicine will be presented, which continue to support innovation as well as progress in personalized cancer care. This includes new data from the Phase II Profiler02 study,* which investigates the use of a comprehensive genomic profiling testing panel from Foundation Medicine, with the aim of informing possible treatment decisions for patients based on their tumor\u2019s unique genomic information.\n<\/p>\n

\nData from the imCORE network<\/b>\n<\/p>\n

\nAdditionally, three abstracts from the Immunotherapy Centers Of Research Excellence (imCORE) Network will be presented at ASCO: a Phase I study** investigating autogene cevumeran (an mRNA-based individualized neoantigen-specific immunotherapy [iNeST]***) in the adjuvant setting of pancreatic ductal adenocarcinoma; a data mining study** evaluating intermediate endpoints for survival in metastatic breast cancer in the real-world setting; and a study identifying mechanisms of acquired resistance to immune checkpoint blockade.**\n<\/p>\n

\nimCORE is an academic-industry network for scientific collaboration. Established by Genentech and connecting experts from 26 leading institutions around the globe, imCORE is committed to advancing and accelerating cancer immunotherapy research. imCORE is an example of Genentech\u2019s dedication to collaborating with the global cancer community to further understand cancer biology and immunology, help inform the development of potential future treatment, and transform patients\u2019 lives.\n<\/p>\n

\nGenentech\u2019s data presented at ASCO will feature its efforts to drive innovation and commitment to health equity through delivery of pioneering medicines and personalized cancer care that together improve outcomes for every patient while reducing the cost to society, inclusive clinical trials that remove barriers to participation, partnerships that multiply our ability to address challenges in cancer care, and bringing innovation into earlier stages of disease to maximize a chance of cure.\n<\/p>\n

\nOverview of key presentations featuring Genentech medicines<\/b>\n<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

\nMedicine<\/b>\n<\/p>\n<\/td>\n

\n

\nAbstract title<\/b>\n<\/p>\n<\/td>\n

\n

\nAbstract number<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nBlood cancer<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nGlofitamab\n<\/p>\n<\/td>\n

\n

\nGlofitamab in patients (pts) with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) and \u22652 prior therapies: Pivotal Phase II expansion results\n<\/p>\n<\/td>\n

\n

\n#7500\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nMosunetuzumab\n<\/p>\n<\/td>\n

\n

\nCELESTIMO: a Phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have received \u22651 line of systemic therapy\n<\/p>\n<\/td>\n

\n

\n#TPS7588\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nPolivy\n<\/p>\n<\/td>\n

\n

\nAsia subpopulation analysis from the Phase III POLARIX trial\n<\/p>\n<\/td>\n

\n

\n#7558\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nInitial safety run-in results of the Phase III POLARGO trial: polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed\/refractory diffuse large B-cell lymphoma (R\/R DLBCL)\n<\/p>\n<\/td>\n

\n

\n#7551\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nLung cancer<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTiragolumab\n<\/p>\n<\/td>\n

\n

\nSKYSCRAPER-02: primary results of a Phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) plus carboplatin plus etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC)\n<\/p>\n<\/td>\n

\n

\n#LBA8507\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nBreast cancer<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nGiredestrant\n<\/p>\n<\/td>\n

\n

\nNeoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+\/HER2\u2013 eBC): final analysis of the randomized, open-label, international Phase 2 coopERA BC study\n<\/p>\n<\/td>\n

\n

\n#589\n<\/p>\n

\n\u00a0\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nInavolisib\n<\/p>\n<\/td>\n

\n

\nLong-term safety of inavolisib (GDC-0077) in an ongoing Phase 1\/1b study evaluating monotherapy and in combination (combo) with palbociclib (palbo) and\/or endocrine therapy in patients (pts) with PIK3CA-mutated, hormone receptor-positive\/HER2-negative (HR+\/HER2\u2013) metastatic breast cancer (BC)\n<\/p>\n<\/td>\n

\n

\n#1052\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTumor agnostic treatment and personalized healthcare<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nRozlytrek\n<\/p>\n<\/td>\n

\n

\nEfficacy\/safety of entrectinib in patients (pts) with ROS1-positive (ROS1+) advanced\/metastatic NSCLC from the Blood First Assay Screening Trial (BFAST)\n<\/p>\n<\/td>\n

\n

\n#LBA9023\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nRozlytrek\n<\/p>\n<\/td>\n

\n

\nTrial in progress: a randomized Phase 3 study of entrectinib vs crizotinib in patients (pts) with locally advanced\/metastatic ROS1 fusion-positive (fp) NSCLC with or without baseline CNS metastases (mets)\n<\/p>\n<\/td>\n

\n

\n#TPS9141\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nComprehensive genomic profiling\n<\/p>\n

\n(IIS, Centre L\u00e9on B\u00e9rard)\n<\/p>\n<\/td>\n

\n

\nIncreasing targeted therapy options for patients with relapsed cancer with broader somatic gene panel analysis from the primary tumor: The Profiler02 randomized Phase II trial*\n<\/p>\n<\/td>\n

\n

\n#3130\n<\/p>\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nComprehensive genomic profiling\n<\/p>\n<\/td>\n

\n

\nClinical and genomic characteristics of patients with durable benefit from immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (aNSCLC)\n<\/p>\n<\/td>\n

\n

\n#9048\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nComprehensive genomic profiling\n<\/p>\n<\/td>\n

\n

\nctDNA Shed as a Tool to Select Immune Checkpoint Inhibitors (ICPI) with or without Chemotherapy for Patients (pts) with advanced Non-small Cell Lung Cancer (aNSCLC)\n<\/p>\n<\/td>\n

\n

\n#9045\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nComprehensive genomic profiling\n<\/p>\n<\/td>\n

\n

\nTrial in progress: LCMC LEADER Neoadjuvant Screening Trial: LCMC4 Evaluation of Actionable Drivers in Early Stage Lung Cancers\n<\/p>\n<\/td>\n

\n

\n#TPS8596\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nReal world data\n<\/p>\n<\/td>\n

\n

\nA real world (rw) evidence study quantifying the clinical value of multi-gene testing in early-stage lung adenocarcinoma (LUAD)\n<\/p>\n<\/td>\n

\n

\n#8525\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nReal world data\n<\/p>\n<\/td>\n

\n

\nReal world analysis of quantitative MET copy number (CN) as a biomarker in advanced NSCLC (aNSCLC)\n<\/p>\n<\/td>\n

\n

\n#9123\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nReal world data\n<\/p>\n<\/td>\n

\n

\nAncestry-based differences in gene alterations in non-small cell lung cancer: real-world data using genetic ancestry analysis\n<\/p>\n<\/td>\n

\n

\n#9125\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nimCORE,\n<\/p>\n

\nISR, Genentech\n<\/p>\n<\/td>\n

\n

\nIdentifying mechanisms of acquired immune escape from sequential, paired biopsies**\n<\/p>\n<\/td>\n

\n

\n#2519\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nimCORE\n<\/p>\n

\nISR, Dana-Farber Cancer Institute\n<\/p>\n<\/td>\n

\n

\nReal-World Progression-Free Survival (rwPFS) and Time to Next Line of Therapy (TTNT) as Intermediate Endpoints for Survival in Metastatic Breast Cancer: A Real World Experience**\n<\/p>\n<\/td>\n

\n

\n#6520\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nimCORE\n<\/p>\n

\nISR, Memorial Sloan Kettering Cancer Center\n<\/p>\n<\/td>\n

\n

\nPhase I Trial of Adjuvant Autogene Cevumeran, an Individualized mRNA Neoantigen Vaccine, for Pancreatic Ductal Adenocarcinoma**\n<\/p>\n<\/td>\n

\n

\n#2516\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\n* IIS, investigator-initiated study\n<\/p>\n

\n** ISR, institution-sponsored research\n<\/p>\n

\n*** jointly developed by Genentech and BioNTech\n<\/p>\n

\nAbout Polivy\u00ae (polatuzumab vedotin-piiq)<\/b>\n<\/p>\n

\nPolivy is a first-in-class anti-CD79b antibody-drug conjugate (ADC). The CD79b protein is expressed specifically in the majority of B cells, an immune cell impacted in some types of non-Hodgkin\u2019s lymphoma (NHL), making it a promising target for the development of new therapies. Polivy binds to CD79b and destroys these B cells through the delivery of an anti-cancer agent, which is thought to minimize the effects on normal cells. Polivy is being developed by Genentech using Seagen ADC technology and is currently being investigated for the treatment of several types of NHL.\n<\/p>\n

\nPolivy U.S. Indication<\/b>\n<\/p>\n

\nPolivy is a prescription medicine used with other medicines, bendamustine and a rituximab product, to treat diffuse large B-cell lymphoma in adults who have progressed after at least two prior therapies.\n<\/p>\n

\nThe accelerated approval of Polivy is based on a type of response rate. There are ongoing studies to confirm the clinical benefit of Polivy.\n<\/p>\n

\nImportant Safety Information<\/b>\n<\/p>\n

\nPossible serious side effects<\/b>\n<\/p>\n

\nEveryone reacts differently to Polivy therapy, so it\u2019s important to know what the side effects are. Some people who have been treated with Polivy have experienced serious to fatal side effects. <\/b>A patient\u2019s doctor may stop or adjust a patient\u2019s treatment if any serious side effects occur. Patients must contact their healthcare team if there are any signs of these side effects.<\/b>\n<\/p>\n

\nNerve problems in arms and legs: <\/b>This may happen as early as after the first dose and may worsen with every dose. If a patient already has nerve pain, Polivy may make it worse. The patient\u2019s doctor will monitor for signs and symptoms, such as changes in sense of touch, numbness or tingling in hands or feet, nerve pain, burning sensation, any muscle weakness, or changes to walking patterns\n<\/p>\n